Drugs / Human CD19-CD22 Targeted T Cells Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05223686 | Feb 2022 → Jun 2023 | acute lymphoblastic leukemia | Hrain Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human CD19-CD22 Targeted T Cells Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05223686 ↗ |
| Modality | Cell therapy | “CD19-CD22 CAR+ T cells” NCT05223686 ↗ |
| Target | CD19 | “CD19-CD22 CAR+ T cells” NCT05223686 ↗ |
| Target | CD22 | “CD19-CD22 CAR+ T cells” NCT05223686 ↗ |